7,874 press releases indexed under healthcare.
Clinical and real-world data underscore the importance of real-time intraoperative detection of residual cancer as breast cancer care continues to move toward more personalized, de-escalated treatment approaches. WALTHAM, Mass., Sept. 15, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in...
Multidisciplinary healthcare organization earns its highest ranking to date at No. 1,230 nationally and ranks No. 135 in Healthcare and Medical HERNDON, Va., Sept. 15, 2026 /PRNewswire/ -- RxWellness Spine & Health has been named to the 2026 Inc. 5000 list of the fastest-growing private...
NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Clear Future's FC2 Female Condom holds a first-of-its-kind event to celebrate Global Female Condom Day in Manhattan's Union Square. On Sept 15, 2026 from 11am to 4pm, FC2's "Overdue Advice" event brings reproductive health professionals to Union...
(PR-inside.com) Company plans to integrate telemedicine into its verified health intelligence platform and opens a ten-seat Founding Physician Cohort spanning GLP-1 and metabolic care, hormone and menopause health, and physician-directed therapies for men and women. MIAMI, FL / ACCESS Newswire / September 15, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced plans to integrate telemedicine capabilities into its verified health intelligence platform and opened applications for its Founding Physician Cohort. Millions of Americans now use GLP-1 medications, and millions more are asking whether these therapies may be appropriate for them. This rapid expansion has exposed significant gaps in the ..
PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:
Company plans to integrate telemedicine into its verified health intelligence platform and opens a ten-seat Founding Physician Cohort spanning GLP-1 and metabolic care, hormone and menopause health, and physician-directed therapies for men and women.
AUSTIN, Texas, Sept. 15, 2026 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical LLC today announced the expansion of its ZTECH-P™ powder drug-delivery platform into pulmonary delivery with the introduction of AriesMR™, a reloadable active dry powder inhaler designed for controlled pulmonary administration of pharmaceutical powders without reliance on patient-generated inspiratory energy for powder aerosolization or the use of CFC/HFA propellants.
Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval.The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participation is...
New partnership brings curated, licensed music into care.coach's companion experience, giving participants more reasons to engage every day. SAN FRANCISCO, Sept. 15, 2026 /PRNewswire-PRWeb/ -- care.coach, a leader in digital health solutions for older adults and individuals with...
NEW YORK, NY and TOKYO - September 15, 2026 ( NEWMEDIAWIRE ) - Instinct Bio Technical Company Holdings Inc. (Nasdaq Symbols: BIOT, BIOTW) (“Instinct Bio” or the “Company”) today announced that on September 9, 2026 and September 10, 2026 it received notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), as described below. On September 9, 2026, Nasdaq notified the Company that because the market value of the Company’s listed securities (“MVLS”) was below US$50,000,000 from July 28, 2026 through September 8, 2026, the Company no longer complies with the minimum requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rules 5450(b)(2)(A) (the “MVLS Requirement”). Nasdaq also noted that the Company does not currently satisf
Health systems see 28% of care gaps scheduled and 300% more missed visits rescheduled with personalized agent follow-up to each patient SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Luma Health, the Operational AI platform for healthcare, today announced new agentic outreach workflows to...
Savings Increased With Duration of Program Exposure, Reaching 31.9% ($462 Per Member Per Month) Following a Nine-Month Implementation Window INDIANAPOLIS, IN - September 15, 2026 ( NEWMEDIAWIRE ) - DecisionRx, Inc., a pharmacist-led medication optimization company, today announced findings from a new study of Medicare Accountable Care Organization (ACO) beneficiaries. The study found that when compared against matched controls, participation in the DecisionRx Medication Therapy Optimization (MTO) program was associated with a 19.4% reduction in total medical costs ($246 per member per month; p < 0.001). The intervention effect grew to 31.9% ($462 per member per month; p < 0.001) after 9 months of program exposure. Cost reductions were concentrated in acute and facility-based care. Co